Application prospect of circular RNA-based neoantigen vaccine in tumor immunotherapy

Area of Science:

• Oncology
• Immunology
• Biotechnology

Background:

• Neoantigens, derived from tumor-specific mutations, are ideal targets for cancer vaccines.
• Current neoantigen vaccine strategies (peptide, DNA, mRNA) face developmental challenges.
• Circular RNA (circRNA) emerges as a novel platform for vaccine development due to its stability and coding potential.

Purpose of the Study:

• To review the feasibility of using circRNA to encode neoantigens for therapeutic vaccines.
• To summarize the construction and in vitro mechanisms of circRNA-based neoantigen vaccines.
• To discuss the advantages, disadvantages, and potential combination immunotherapies for circRNA vaccines.

Main Methods:

• Literature review on circRNA technology in cancer vaccines.
• Analysis of circRNA stability and protein-coding capacity for neoantigen expression.
• Examination of in vitro mechanisms and preclinical data of circRNA vaccines.
• Discussion of comparative advantages over existing vaccine platforms.

Main Results:

• Circular RNA demonstrates high stability and efficient protein translation, making it suitable for neoantigen vaccines.
• The construction of circRNA vaccines involves specific design and production methodologies.
• In vitro studies suggest circRNA vaccines can elicit robust anti-tumor immune responses.
• circRNA vaccines offer potential advantages in terms of immunogenicity and delivery.

Conclusions:

• Circular RNA represents a promising and potentially superior platform for developing next-generation neoantigen vaccines.
• Further research into circRNA vaccine construction and clinical applications is warranted.
• Combination strategies involving circRNA vaccines and other immunotherapies may enhance treatment efficacy.